Therapeutic monitoring of drug plasma concentrations and improved outcomes in CML

Clinical Advances in Hematology and Oncology

Volumn 7, Issue 2 SUPPL. 4, 2009, Pages 3-5

  Larson, Richard A ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTOCHROME P450; IMATINIB; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANEMIA; ARTICLE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPLETE CYTOGENIC RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG UPTAKE; DRUG WITHDRAWAL; FLUID RETENTION; GENE MUTATION; HUMAN; MYALGIA; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; RASH; SIDE EFFECT; TREATMENT OUTCOME; RANDOMIZED CONTROLLED TRIAL; REMISSION;

DRUG MONITORING; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEDICATION ADHERENCE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REMISSION INDUCTION;

EID: 65649121204     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Soverini S, Martinelli G, Iacobucci I, Baccarani M. Imatinib mesylate for the treatment of chronic myeloid leukemia. Expert Rev Anticancer Ther. 2008;8:853-864.
2. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408-2417.
3. Gschwind HP, Pfaar U, Waldmeier F, et al. Metabolism and disposition of imatinib mesylate in healthy volunteers. Drug Metab Dispos. 2005;33:1503-1512.
4. Peng B, Lloyd P, Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44:879-894.
5. Peng B, Dutreix C, Mehring G, et al. Absolute bioavailability of imatinib (Glivec) orally versus intravenous infusion. J Clin Pharmacol. 2004;44:158-162.
6. Peng B, Hayes M, Resta D, et al. Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients. J Clin Oncol. 2004;22:935-942.
7. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008;111:4022-4028.
8. Jabbour E, Kantarjian H, Jones D, et al. Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate. Leukemia. 2006;20:1767-1773.
9. Feng W, Henk H, Thomas S, et al. Compliance and persistency with imatinib. Program and abstracts of the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, Georgia; June 2-6, 2006: Abstract 6038.
10. Darkow T, Henk HJ, Thomas SK, et al. Treatment interruptions and non-adherence with imatinib and associated healthcare costs: a retrospective analysis among managed care patients with chronic myelogenous leukaemia. Pharmacoeconomics. 2007;25:481-496.
11. Tsang J, Rudychev I, Pescatore SL. Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). Program and abstracts of the 42nd Annual Meeting of the American Society of Clinical Oncology; Atlanta, Georgia; June 2-6, 2006: Abstract 6119.
12. Reed SD, Anstrom KJ, Ludmer JA, Glendenning GA, Schulman KA. Cost-effectiveness of imatinib versus interferon-alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004;101: 2574-2583.
13. Bolton A, Peng B, Hubert M, et al. Effect of rifampicin (a potent inducer of CYP450 3A4) on the pharmacokinetics of Gleevec™ (Glivec®, STI571, imatinib). Blood. 2002;100:214b.
14. Illmer T, Schaich M, Platzbecker U, et al. P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate. Leukemia. 2004;18:401-408.
15. Thomas J, Wang L, Clark RE, Pirmohamed M. Active transport of imatinib into and out of cells: implications for drug resistance. Blood. 2004;104:3739-3745.
16. White DL, Saunders VA, Dang P, et al. CML patients with low OCT-1 activity achieve better molecular responses on high dose imatinib than on standard dose. Those with high OCT-1 activity have excellent responses on either dose: a TOPS correlative study. Program and abstracts of the 50th American Society of Hematology Annual Meeting and Exposition; San Francisco, California; December 6-9, 2008: Abstract 3187.
17. Takane H, Shikata E, Otsubo K, Higuchi S, Ieiri I. Polymorphism in human organic cation transporters and metformin action. Pharmacogenomics. 2008;9: 415-422.
18. Picard S, Titier K, Etienne G, et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood. 2007;109:3496-3499.
19. Guilhot F, Hughes TP, Cortes J, et al. Imatinib (IM) pharmacokinetic (PK) exposure and its correlation with clinical outcome in patients with chronic-phase chronic myeloid leukemia (CML-CP) for 400 mg and 800 mg daily doses (tyrosine kinase dose optimization study [TOPS]). Program and abstracts of the 50th American Society of Hematology Annual Meeting and Exposition; San Francisco, California; December 6-9, 2008: Abstract 447.
20. Cortes J, Baccarani M, Guilhot F, et al. First report of the TOPS study: a randomized phase III trial of 400mg vs 800mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints. Program and abstracts of the 13th Congress of the European Hematology Association; June 14, 2008: Abstract 402.
21. Baccarani M, Castagnetti F, Simonsson B, et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European Leukemianet prospective study comparing 400 mg and 800 mg frontline. Blood. 2008; 112: 185.
22. Sokal JE, Baccarani M, Russo D, Tura S. Staging and prognosis in chronic myelogenous leukemia. Semin Hematol. 1988;25:49-61.
23. Saglio G, Pane F, Martinelli G. State-of-the-art monitoring for patients with chronic myeloid leukemia. American Society of Clinical Oncology Education Book 2008: Available at http://edbook.ascopubs.org/cgi/content/ abstract/2008/1/313.
24. Molimard M, Bouchet S, Etienne G, et al. Management of chronic myelogenous leukemia using therapeutic drug monitoring of imatinib: the French experience of a centralized laboratory. Program and abstracts of the 50th American Society of Hematology Annual Meeting and Exposition; San Francisco, California; December 6-9, 2008: Abstract 3222.